A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Insulin degludec
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Anniston,Birmingham,Chandler,Fountain Hills,Glendale,Glendale,Glendale,Phoenix,Tucson,Buena Park,Concord,Downey,Duarte,Fresno,La Jolla,Lancaster,Lomita,Los Alamitos,Los Angeles,Moreno Valley,Northridg, Canada,Denmark,Estonia,Germany,Greece,Hungary,Norway,Poland,Puerto Rico,Romania,Serbia,United States
- Phase
- Phase 3
- Start date
- Mar 13, 2017
- End date
- Mar 04, 2019
- Enrollment
- 1609 participants
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
This trial is conducted in Europe and North America. The aim of the trial is to compare the
 efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with
 type 2 diabetes mellitus inadequately treated with basal insulin with or without oral
 antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended
 to allow for a full 36 weeks (maintenance 2 period) of the use of the new process.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03078478
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03078478 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 1609 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.